Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Creative Medical Technology Holdings (CELZ) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Creative Medical Technology Holdings (CELZ) over the last 9 years, with Q1 2025 value amounting to 55349.27%.

  • Creative Medical Technology Holdings' EBITDA Margin changed N/A to 55349.27% in Q1 2025 from the same period last year, while for Sep 2025 it was 101379.43%, marking a year-over-year decrease of 501979200.0%. This contributed to the annual value of 52216.92% for FY2024, which is 102289900.0% up from last year.
  • As of Q1 2025, Creative Medical Technology Holdings' EBITDA Margin stood at 55349.27%.
  • In the past 5 years, Creative Medical Technology Holdings' EBITDA Margin ranged from a high of 1855.31% in Q3 2022 and a low of 62857.8% during Q4 2024
  • Over the past 5 years, Creative Medical Technology Holdings' median EBITDA Margin value was 20316.32% (recorded in 2024), while the average stood at 25661.6%.
  • Over the last 5 years, Creative Medical Technology Holdings' EBITDA Margin had its largest YoY gain of 64790500bps in 2022, and its largest YoY loss of -315787100bps in 2022.
  • Over the past 5 years, Creative Medical Technology Holdings' EBITDA Margin (Quarter) stood at 2173.64% in 2021, then crashed by -1453bps to 33752.35% in 2022, then plummeted by -75bps to 59061.3% in 2023, then fell by -6bps to 62857.8% in 2024, then grew by 12bps to 55349.27% in 2025.
  • Its EBITDA Margin stands at 55349.27% for Q1 2025, versus 62857.8% for Q4 2024 and 20316.32% for Q2 2024.